Literature DB >> 24894481

Cognitive impact of cytotoxic agents in mice.

R Seigers1, M Loos, O Van Tellingen, W Boogerd, A B Smit, S B Schagen.   

Abstract

RATIONALE AND
OBJECTIVES: Adjuvant chemotherapy is associated with changes in cognition in a subgroup of cancer patients. Chemotherapy is generally given as a combination of cytotoxic agents, which makes it hard to define the agent responsible for these observed changes. Literature on animal experiments has been difficult to interpret due to variance in experimental setup.
METHODS: We examined the effects of cytotoxic agents administered separately on various cognitive measures in a standardized animal model. Male C57Bl/6 mice received cyclophosphamide, docetaxel, doxorubicin, 5-fluorouracil, methotrexate, or topotecan. These agents represent different compound classes based on their working mechanism and are frequently prescribed in the clinic. A control group received saline. Behavioral testing started 2 or 15 weeks after treatment and included testing general measures of behavior and cognitive task performance: spontaneous behavior in an automated home cage, open field, novel location recognition (NLR), novel object recognition (NOR), Barnes maze, contextual fear conditioning, and a simple choice reaction time task (SCRTT).
RESULTS: Cyclophosphamide, docetaxel, and doxorubicin administration affected spontaneous activity in the automated home cage. All cytotoxic agents affected memory (NLR and/or NOR). Spatial memory measured in the Barnes maze was affected after administration with doxorubicin, 5-fluorouracil, and topotecan. Decreased inhibition in the SCRTT was observed after treatment with cyclophosphamide, docetaxel, and topotecan.
CONCLUSIONS: Our data show that, in mice, a single treatment with a cytotoxic agent causes cognitive impairment. Not all cytotoxic agents affected the same cognitive domains, which might be explained by differences in working mechanisms of the various agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24894481     DOI: 10.1007/s00213-014-3636-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  59 in total

1.  Object recognition testing: statistical considerations.

Authors:  Sven Akkerman; Jos Prickaerts; Harry W M Steinbusch; Arjan Blokland
Journal:  Behav Brain Res       Date:  2012-03-28       Impact factor: 3.332

2.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

3.  Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats.

Authors:  Yan Li; Veena Vijayanathan; Maria E Gulinello; Peter D Cole
Journal:  Pharmacol Biochem Behav       Date:  2009-11-01       Impact factor: 3.533

4.  Chemotherapy associated central nervous system damage.

Authors:  Jörg Dietrich
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  Learning impairments and motor dysfunctions in adult Lhx5-deficient mice displaying hippocampal disorganization.

Authors:  R Paylor; Y Zhao; M Libbey; H Westphal; J N Crawley
Journal:  Physiol Behav       Date:  2001-08

6.  Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

7.  Anticancer agents are potent neurotoxins in vitro and in vivo.

Authors:  Wojciech Rzeski; Susanne Pruskil; Alexander Macke; Ursula Felderhoff-Mueser; Anne Katrin Reiher; Friederike Hoerster; Corina Jansma; Bozena Jarosz; Vanya Stefovska; Petra Bittigau; Chrysanthy Ikonomidou
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

8.  Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3).

Authors:  Yoshiaki Kitamura; Masakazu Hirouchi; Hiroyuki Kusuhara; John D Schuetz; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2008-08-21       Impact factor: 4.030

9.  Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer.

Authors:  Miyoung Yang; Joong-Sun Kim; Juhwan Kim; Sungwoong Jang; Sung-Ho Kim; Jong-Choon Kim; Taekyun Shin; Hongbing Wang; Changjong Moon
Journal:  Brain Res Bull       Date:  2012-07-13       Impact factor: 4.077

10.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

Authors:  Joerg Dietrich; Ruolan Han; Yin Yang; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2006
View more
  28 in total

Review 1.  Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.

Authors:  Robson da Costa; Giselle F Passos; Nara L M Quintão; Elizabeth S Fernandes; João Raphael L C B Maia; Maria Martha Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2020-06-03       Impact factor: 8.739

2.  Chemo brain: From discerning mechanisms to lifting the brain fog-An aging connection.

Authors:  Anna Kovalchuk; Bryan Kolb
Journal:  Cell Cycle       Date:  2017-06-28       Impact factor: 4.534

Review 3.  Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities.

Authors:  Kelley R Jordan; Brett R Loman; Michael T Bailey; Leah M Pyter
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

4.  A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype.

Authors:  Tamar C Demby; Olga Rodriguez; Camryn W McCarthy; Yi-Chien Lee; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck
Journal:  Behav Brain Res       Date:  2020-02-03       Impact factor: 3.332

5.  Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.

Authors:  Marie Lange; Natacha Heutte; Olivier Rigal; Sabine Noal; Jean-Emmanuel Kurtz; Christelle Lévy; Djelila Allouache; Chantal Rieux; Johan Lefel; Bénédicte Clarisse; Corinne Veyret; Philippe Barthélémy; Nadine Longato; Hélène Castel; Francis Eustache; Bénédicte Giffard; Florence Joly
Journal:  Oncologist       Date:  2016-07-29

6.  Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.

Authors:  Timothy J Flanigan; Julie E Anderson; Ikram Elayan; Antiño R Allen; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

7.  Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.

Authors:  Lauren E Himmel; Maryam B Lustberg; A Courtney DeVries; Ming Poi; Ching-Shih Chen; Samuel K Kulp
Journal:  Exp Toxicol Pathol       Date:  2016-08-21

8.  Doxorubicin and cyclophosphamide induce cognitive dysfunction and activate the ERK and AKT signaling pathways.

Authors:  Kaliris Y Salas-Ramirez; Ciara Bagnall; Leslie Frias; Syed A Abdali; Tim A Ahles; Karen Hubbard
Journal:  Behav Brain Res       Date:  2015-06-19       Impact factor: 3.332

9.  Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment.

Authors:  Angie C A Chiang; Xiaojiao Huo; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

Review 10.  Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits.

Authors:  Rex M Philpot
Journal:  Neurochem Res       Date:  2015-02-05       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.